#DonaldTrump news $SPY collapsed! $VIX $AAPL $NFLX $TSLA

Wow! The market must be in a fragile state for the $SPY to have dropped 1% within 30 minutes of trading on news about Donald Trump and Michael Flynn. It’s as if the market isn’t going to require much negative news to start putting the brakes on this 2017 bull run.

By Ryan Vlastelica Dec. 1, 2017, 11:23 a.m. EST U.S. stocks fell sharply on Friday, turning lower in midday trading following reports that Michael Flynn will testify about President Donald Trump. The Dow Jones Industrial Average fell 162 points, or 0.7%, to 24,116. The S&P 500 lost 18 points to 2,630, a drop of 0.6 https://www.marketwatch.com/story/us-stocks-turn-lower-following-reports-flynn-will-testify-about-trump-2017-12-01


Happy #Thanksgiving Save 30-60% https://profit.ly/sales/turkey?aff=2295 #BlackFriday2017 @TimothySykes $MARA $SRAX $GROW $MICT $ACST #trading #invest

I subscribed to @TimothySykes #pennystock #trading service back in 2012, I was a member for 2 years. The trading methods which I learned through this service have helped me along my path of becoming a consistently profitable trader. I do recommend his educational products and services.

You will learn how to identify companies which are hyping their stock, which causes the share price to become artificially inflated. Thus you will find companies such as $VIBI where you look to sell short around the highs of $2.00 and then look to buy-to-cover your shares back around $1.00 into the massive sell-off. You will need the right stock broker in order to participate in these types of stock plays and you will learn which broker to use from Timothy Sykes service. VIBi is a stock which I recently had a nice 50% profit on my trade by doing exactly what Tim teaches with his trading method.

If you are interested in learning from him as well, follow this link to see all the products available along with the 30-60% savings, https://profit.ly/sales/turkey?aff=2295

Happy #Thanksgiving Save 30-60% @TimothySykes #pennystock #trading services. #BlackFriday2017 https://profit.ly/sales/turkey?aff=2295

$ILIU Orig3n™ Acquires Interleukin Genetics, a Genetics-Based Personalized Health Company, to Advance the Futu re of Health Faster

PRESS RELEASE

Orig3n™ Acquires Interleukin Genetics, a Genetics-Based Personalized Health Company, to Advance the Future of Health Faster
By
Published: Nov 22, 2017 3:02 p.m. ET

The addition will support the accelerated growth of Orig3n’s direct-to-consumer genetic assessment business

BOSTON, Nov. 22, 2017 /PRNewswire/ — Orig3n, Inc., a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine research, today announced the acquisition of Interleukin Genetics CLIA laboratory and their remaining assets. Interleukin Genetics’ technology will become a core component of Orig3n’s DNA test business to empower more people to take charge of their health through genetic insights.

Interleukin Genetics brings exceptional and valuable assets to Orig3n, including a CLIA-Certified Genetics Laboratory in Waltham, Massachusetts. The automated genotyping lab is fully-licensed for testing in all 50 U.S. states and is capable of processing over one million samples per year. In addition to the company’s state-of-the-art technology and its HIPAA and HITECH compliance, Interleukin Genetics also brings its ILUSTRA™ Inflammation Management Program and its Inherent Health® genetic tests for nutritional needs, weight management, heart health, and bone health to Orig3n. All personalized genetic tests will be consolidated under the Orig3n brand.

"Once we met with Interleukin Genetics, we saw a natural alignment between the two organizations regarding our shared commitment to a future of personalized health," said Robin Y. Smith, CEO of Orig3n. "With our trajectory of accelerated growth, we couldn’t imagine a better fit for acquisition. We are very pleased to be welcoming Interleukin Genetics to Orig3n."

Orig3n’s regenerative medicine research lab will remain in Boston’s Innovation District and the genetic testing will be consolidated to Interleukin Genetics’ CLIA laboratory. Rene Oda, previously the Director of Technology at Interleukin Genetics will join Orig3n as the Director of Product Management and Dr. Lynn Doucette-Stamm, joins as Senior Vice President of Development and Clinical Operations.

"We are looking forward to using our skillsets with Orig3n’s to expand the array of direct-to-consumer DNA tests," said Dr. Lynn Doucette-Stamm. "We see innovative growth opportunities ahead and we’re very excited to be joining a company focused on furthering the common good and advancing the future of health through genetics and regenerative medicine research."

About ORIG3N, Inc.
Founded in 2014, ORIG3N exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we’re on a mission to accelerate the future of health. For more information, visit www.orig3n.com.

Orig3n’s Guiding Beliefs:

We believe people should have direct, affordable access to information about their genes and their health.
We believe that when people better understand the links between genes, health, and behavior, they can make educated, proactive choices about their future.
We believe people should be in control of how their genetic information is used.
We believe diagnosing and treating disease shouldn’t be a matter of trial and error.
About Interleukin Genetics, Inc.Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/orig3n-acquires-interleukin-genetics-a-genetics-based-personalized-health-company-to-advance-the-future-of-health-faster-300561135.html

SOURCE Orig3n, Inc.

Copyright (C) 2017 PR Newswire. All rights reserved

https://www.marketwatch.com/story/orig3ntm-acquires-interleukin-genetics-a-genetics-based-personalized-health-company-to-advance-the-future-of-health-faster-2017-11-22?siteid=nbsh

$ACST massive breakout +144%, can I get my $1.32 long stocks back?

$ACST I was long from ~$1.32 avg in anticipation of a large move such as what we saw yesterday. However, I took my profits at $1.60 in pre-market, didn’t realize it was going to open near $3.00! The early pre-market price premiums are usually a good time to take profits, but today it was not. Maybe no more non-regular hour trades…?

$ALRT #tape #reading for #Pennystock #Daytraders 09-19-2017

ALRT-1-minute-chart-09-19-2017
ALRT-otcmarkets-company-profile
September 19, 2017 – 10:02 AM EDT
FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature

IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs

RICHMOND, VA–(Marketwired – September 19, 2017) – The United States Food and Drug Administration (FDA) has granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.

The ALRT system with IDA uses the American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) insulin dosing guidelines to process patient blood glucose values to provide reference doses based on the guidelines. The reference doses are compared with the patient’s current insulin dose(s) to determine whether current insulin dosing is optimal. If there is a difference between the patient’s current insulin dose(s) and the reference doses, this difference will be flagged and a notification sent to the managing healthcare provider (HCP) suggesting an insulin dose review. The blood glucose values are uploaded directly from the patient’s blood glucose meter.

“With FDA clearance for Insulin Dose Adjustment, it will simplify insulin dosing for healthcare providers,” said Sidney Chan CEO of ALR Technologies. “First, it makes it easy for healthcare providers to titrate insulin dosing for new insulin patients. Second, it will help healthcare providers to prescribe optimal dose(s) for patients on insulin, addressing the so called ‘insulin glass ceiling’. IDA is designed to ensure that patients get an effective and timely dose based on accurate data about their specific needs,” said Chan. Insulin manufacturer Novo Nordisk estimates that morbidity and mortality rates resulting from medication errors add an estimated $1,900 per patient to total U.S. health care costs and remember, about half of that is mistakes with insulin.1

The IDA feature is intended only for insulin-requiring Type 2 diabetes patients to provide the HCP with two reference doses. IDA is not indicated for patients who utilize insulin pumps and it is limited to adults with Type 2 diabetes on fixed dose regimen of insulin.

About ALR Technologies Inc.
ALR Technologies is a medical device company providing an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters. The System processes and streamlines collected data to support clinicians and caregivers to improve patient outcomes and assist health plans to optimize their investments in chronic disease care. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.

1 http://www.diabetesincontrol.com/a-review-of-insulin-errors/

Contact:
Ken Robulak:
727.736.3838
email: info@alrt.com

Source: Marketwired (September 19, 2017 – 10:02 AM EDT)
News by QuoteMedia

Does $GBTC have SEC Suspension and Trading Halt RISK? #BTC #Bitcoin

Maybe SEC halts GBTC soon? They already settled once with the SEC a year ago.
https://www.coindesk.com/bitcoin-investment-trust-50000-settlement/
https://www.sec.gov/litigation/admin/2016/34-78282.pdf

https://www.coindesk.com/third-in-a-month-sec-moves-to-halt-otc-trading-for-bitcoin-firm/

https://www.coindesk.com/sec-warns-public-companies-using-icos-pump-stocks/

Common Stock – Each GBTC share represents ownership of approximately 0.1 bitcoin
$4608 x 0.1 = $460.8

Is $GBTC trading ~2x above what it should be?

https://bravenewcoin.com/news/gbtc-now-trading-60-higher-than-the-underlying-asset-bitcoin/

$LEXG indicates new warrant prices 300% ($0.0021) & 400% ($0.0028) ABOVE today’s market price $0.0007

At the time of this news release today, LEXG has had a trading range of 0.0006 to 0.0009 with the VWAP of $0.00073 on 91,212,877 shares traded.  So in today’s PR when the company announced reducing conversion discount by 50% and in consideration of the significant reduction in debt, each fund will receive two new warrants, which will have a conversion mechanism 300% and 400% above today’s market price!  So a simple calculation would suggest that the conversion prices are equal to $0.0021 (0.0007 x 300%) and $0.0028 (0.0007 x 400%).  What this tells me is that LEXG will need to trade at or above 0.0021 and 0.0028 in order for the debt holders to begin converting their debt into shares.  At today’s market price of $0.0007, I think that we are in for a good ride to the upside!  I have written about $LEXG in the past being a potential 10 bagger stock investment potential, and I still believe this to be true.

LEXG-daily-chart-08-07-2017

Here is the official PRESS RELEASE:

Lithium Exploration Group Announces 50% Reduction in Conversion Feature of Existing Debt Eliminating More Than Four Billion Shares of Dilution

Published: Aug 7, 2017 12:00 p.m. ET

PHOENIX, August 7, 2017 /PRNewswire via COMTEX/ — PHOENIX, August 7, 2017 /PRNewswire/

Lithium Exploration Group Inc. (USOTC: LEXG) announced today that it has come to terms with two major debt holders to restructure all of their convertible notes, reducing conversion discount by 50%. In consideration of the significant reduction in debt, each fund will receive two new warrants, which will have a conversion mechanism 300% and 400% above today’s market price. The collective view of the company and the debt holders is that Lithium Exploration Group is in a significantly better position than it has been in the past and the heavily dilutive terms of the debt were not sustainable for the company or its shareholders.

“This is exciting news and should show everyone the level of confidence that the debt holders have in the company’s current position,” commented CEO, Alex Walsh. “They have conceded a significant portion of their debt rights in return for warrants that produce a significant incentive to see long-term price appreciation in the LEXG security. This restructuring truly has all parties incentivized in the same direction and should show significant benefit to our existing shareholders for a long time to come.”

About Lithium Exploration Group

Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is focused on testing the Sonic Cavitation Ltd. technology and the acquisition of oil and gas related assets in the US and Canada. Lithium Exploration Group is traded on the OTC Markets under the symbol LEXG.

Website: http://www.lithiumexplorationgroup.com.

Safe Harbor Statement

This news release contains “forward-looking statements”. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact InfoShanon Chilson +1-480-641-4790 info@lithiumexplorationgroup.com

SOURCE Lithium Exploration Group Inc.

Copyright (C) 2017 PR Newswire. All rights reserved

http://www.marketwatch.com/story/lithium-exploration-group-announces-50-reduction-in-conversion-feature-of-existing-debt-eliminating-more-than-four-billion-shares-of-dilution-2017-08-07?siteid=nbsh

$LEXG Lithium Exploration Group Announces Buyout of Largest Debt Holder PHOENIX, August 4, 2017 PRNewswire/

August 4, 2017 – 12:12 PM EDT
Print
Email Article
Font Down
Font Up
Charts
LEXG 0.0008 0.0001

Today 5d 1m 3m 1y 5y 10y

Lithium Exploration Group Announces Buyout of Largest Debt Holder
PHOENIX, August 4, 2017 /PRNewswire/ —

Lithium Exploration Group, Inc. (OTC-PINK: LEXG) today announced today that its largest Debt holder with over $2.3mm in Debt has been Bought Out by a New Investor Group. The New Investor Group believes in the long term viability of the White Top Oil Investment and that the reserves will be proved out by the new seismic data.

CEO Alex Walsh stated "The timing of the But Out was spurred on by the positive reinforcement of Meir report and the potential 30% upside above and beyond the initial reserves of the property!."

About Lithium Exploration Group

Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is focused on its Western Canada lithium assets, testing its Ultrasonic Generator Technology and the acquisition of oil and gas related assets in Western Canada. Lithium Exploration Group is a fully reporting company traded on the OTC Markets under the symbol LEXG. Website: http://www.lithiumexplorationgroup.com.

Safe Harbor Statement

This news release contains "forward-looking statements". Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CONTACT:
Shanon Chilson
+1-480-641-4790
info

SOURCE Lithium Exploration Group Inc.

Source: PR Newswire (August 4, 2017 – 12:12 PM EDT)

News by QuoteMedia

$NINK Nami Corp.: $1.1 Billion Market Cap That Is Worth Zero by @QuanFunds

$NINK stock chart daily 08-01-2017
$NINK market cap is over 1 billion dollars!

Summary

The company has no real business and zero listed assets.

The only company officer has no observable business experience.

Nami is worthless. But incredibly, is valued at over $1 billion.

Nami Corp. (OTCQB:NINK), previously known as Pack Fuerte, was founded in 2012 and is based in Las Vegas, Nevada. Up until late 2016, the company was looking for backers to fund a business plan to produce a locked compartment inside backpacks and general luggage. The company’s latest business plan du jour is to acquire assets in the form of profitable companies throughout the Asian region. This is just vaporware, as the company has no money and just one manager with no relevant experience in acquiring assets or even running a company.

Mr. Ong Tee Keat has been Chairman, Chief Executive Officer, Secretary and Treasurer at Nami Corp. since December 2016. He served as Political Secretary to the then Housing and Local Government Minister, Datuk Lee Kim Sai, since 1986, and was a Member of the Parliament of Malaysia until 2013 (see here for more information). Prior to 1986, he was a mechanical engineer and wrote a column in a local Chinese newspaper. Mr. Keat may have been a credible political figure for most of his career, but his business experience is lacking, to say the least.

On October 31, 2016, Mr. Keat acquired 60.22% of the company’s shares from Bunloet Sriphanorm, constituting his entire position. Mr. Sriphanorm was the former majority owner of Pack Fuerte, and he subsequently resigned.

Read the full article on seekingalpha.com website